Literature DB >> 31470782

Humoral Immunity Against HDL Particle: A New Perspective in Cardiovascular Diseases?

Nathalie Satta1,2, Miguel A Frias1,2, Nicolas Vuilleumier1,2, Sabrina Pagano1,2.   

Abstract

BACKGROUND: Autoimmune diseases are closely associated with cardiovascular diseases (CVD). Over the last decades, the comprehension of atherosclerosis, the principal initiator of CVD, evolved from a lipidcentered disease to a predominant inflammatory and immune response-driven disease displaying features of autoimmunity against a broad range of auto-antigens, including lipoproteins. Among them, high density lipoproteins (HDL) are important actors of cholesterol transport and bear several anti-atherogenic properties, raising a growing interest as therapeutic targets to decrease atherosclerosis and CVD burden, with nevertheless rather disappointing results so far. Reflecting HDL composition complexity, autoimmune responses and autoantibodies against various HDL components have been reported.
RESULTS: In this review, we addressed the important complexity of humoral autoimmunity towards HDL and particularly how this autoimmune response could help improving our understanding of HDL biological implication in atherosclerosis and CVD. We also discussed several issues related to specific HDL autoantibody subclasses characteristics, including etiology, prognosis and pathological mechanisms according to Rose criteria.
CONCLUSION: Finally, we addressed the possible clinical value of using these antibodies not only as potential biomarkers of atherogenesis and CVD, but also as a factor potentially mitigating the benefit of HDL-raising therapies. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  HDL; atherosclerosis; auto-antigens; autoantibodies; biomarker; cardiovascular diseases.

Mesh:

Substances:

Year:  2019        PMID: 31470782     DOI: 10.2174/1381612825666190830164917

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  2 in total

1.  Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A-1?

Authors:  Nicolas Vuilleumier; Sabrina Pagano; Burkhard Ludewig; Kristin Schmiedeberg; Christoph Haller; Johannes von Kempis; Andrea Rubbert-Roth
Journal:  Eur J Clin Invest       Date:  2021-11-29       Impact factor: 5.722

2.  Prognostic and therapeutic considerations of antibodies against c-ter apolipoprotein A-1 in the general population.

Authors:  Nicolas Vuilleumier; Panagiotis Antiochos; Pedro Marques-Vidal; Sabrina Pagano; Julien Virzi; Nathalie Satta; Oliver Hartley; Hubert Gaertner; Karim J Brandt; Fabienne Burger; Fabrizio Montecucco; Gerard Waeber; François Mach; Peter Vollenweider
Journal:  Clin Transl Immunology       Date:  2020-12-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.